GSK Can't Use Prometheus To Nix Classen's Patent Suit
A Maryland federal judge on Thursday told GlaxoSmithKline PLC that it couldn't use the U.S. Supreme Court's recent Prometheus decision to dismiss Classen Immunotherapies Inc.'s lawsuit alleging the pharmaceutical giant infringed...To view the full article, register now.
Already a subscriber? Click here to view full article